Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial

BACKGROUND: Several countries have implemented a 2-dose (2D) human papillomavirus (HPV) vaccination schedule for adolescents based on immunobridging studies. We compared immunogenicity of 2D vs 3-dose (3D) schedules of the quadrivalent vaccine (4vHPV) up to 10 years after the first dose. METHODS: Gi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Infect Dis
Autori principali: Donken, Robine, Dobson, Simon R M, Marty, Kim D, Cook, Darrel, Sauvageau, Chantal, Gilca, Vladimir, Dionne, Marc, McNeil, Shelly, Krajden, Mel, Money, Deborah, Kellner, James, Scheifele, David W, Kollmann, Tobias, Bettinger, Julie A, Liu, Shuzhen, Singer, Joel, Naus, Monika, Sadarangani, Manish, Ogilvie, Gina S
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Articles and Commentaries
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7428395/
https://ncbi.nlm.nih.gov/pubmed/31617568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciz887
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi